Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Pentagon advances Golden Dome missile defense with new Space Force contracts - 2New movies to watch this week: See 'Marty Supreme' in theaters, rent 'Springsteen: Deliver Me from Nowhere,' stream 'Cover-Up' on Netflix
- 3NASA probe captures stunning photos of Earth and moon on the way to infamous asteroid Apophis
- 4Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- 5NASA to bring astronauts home from space station early due to a medical issue
- I read 115 books this year. 'Wuthering Heights,' 'Heart the Lover' and 'The House of My Mother' were among my 10 favorites.
- The Delight of Camper Vans: Choosing the One That Meets Your Requirements
- Top Breakfast Food: What's Your Morning Enjoyment?
- Opening Innovativeness: Moving Thoughts and Tasks
- Fossils unearthed in Morocco are first from little-understood period of human evolution
- Roman around the Christmas tree | Space photo of the day for Dec. 25, 2025
- Well known Tea Brands for Each Tea Sweetheart
- In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
- The Best Computer games Ever
